Last10K.com

Anixa Biosciences Inc (ANIX) SEC Filing 10-K Annual report for the fiscal year ending Saturday, October 31, 2020

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Document and Entity Information - USD ($)
12 Months Ended
Oct. 31, 2020
Jan. 07, 2021
Apr. 30, 2020
Cover [Abstract]   
Entity Registrant NameAnixa Biosciences Inc  
Entity Central Index Key0000715446  
Document Type10-K  
Document Period End DateOct. 31, 2020  
Amendment Flagfalse  
Current Fiscal Year End Date--10-31  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Business Flagtrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 35,235,950
Entity Common Stock, Shares Outstanding 26,076,819 
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2020  

View differences made from one year to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Financial
Other
Filter by Subcategory:
All
Product
Expense
Income
Cash Flow
Other
Inside Anixa Biosciences Inc's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Equity
Consolidated Statements Of Operations
Consolidated Statements Of Operations (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Details)
Business And Funding
Business And Funding (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Impact Of Coronavirus Pandemic
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Income Tax Provision (Benefit) (Details)
Income Taxes - Schedule Of Reconciliation Of Income Taxes (Details)
Leases
Leases (Details Narrative)
Leases (Tables)
Leases - Schedule Of Minimum Lease Payments (Details)
Leases - Schedule Of Operating Lease (Details)
Segment Information
Segment Information (Details Narrative)
Segment Information (Tables)
Segment Information - Schedule Of Segment Information (Details)
Shareholders' Equity
Shareholders' Equity (Details Narrative)
Shareholders' Equity (Tables)
Shareholders' Equity - Schedule Of Option Activity (Details)
Shareholders' Equity - Schedule Of Outstanding And Exercisable (Details)
Shareholders' Equity - Schedule Of Warrants Activity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Changes In Noncontrolling Interest (Details)
Summary Of Significant Accounting Policies - Schedule Of Hierarchy Of Financial Assets (Details)
Summary Of Significant Accounting Policies - Schedule Of Weighted Average Assumptions Used In Estimating Fair Value Of Stock Options (Details)
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-21-000456
Submitted to the SEC: Thu Jan 07 2021 4:15:57 PM EST
Accepted by the SEC: Thu Jan 07 2021
Period: Saturday, October 31, 2020
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001493152-21-000456.htm